3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
3
Gastrointestinal
2
Breast
2
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Wilms Tumor
6
Ovarian Neoplasms
6
Neuroblastoma
5
Testicular Neoplasms
4
Sarcoma
4
Prostatic Neoplasms
4
Osteosarcoma
4
Neuroectodermal Tumors, Primitive, Peripheral
4
Medulloblastoma
4
Kidney Neoplasms
4
Astrocytoma
4
Optic Nerve Glioma
3
Oligodendroglioma
3
Glioma
3
Familial ependymoma
3
Choroid Plexus Neoplasms
3
Central Nervous System Neoplasms
3
Testicular Germ Cell Tumor
2
Teratoma
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Ovarian Germ Cell Cancer
2
Neoplasms
2
Liver Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors
1
Interventions
pembrolizumab
7
Nivolumab
4
Carboplatin
4
Taxes
3
Paclitaxel
3
Gene Expression Profiling
3
rucaparib
2
aflibercept
2
Radiotherapy
2
Polymerase Chain Reaction
2
Leucovorin
2
Irinotecan
2
Interleukin-12 Subunit p35
2
Fluorouracil
2
Drug Therapy
2
Capecitabine
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
veliparib
1
trastuzumab deruxtecan
1
tocilizumab
1
selinexor
1
olaparib
1
liposomal doxorubicin
1
eribulin
1
entinostat
1
dehydroftorafur
1
cc-486
1
cabozantinib
1
belinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
Temozolomide
×
Genitourinary
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled